Sulfonamide compounds for the treatment of neurological conditions

A compound of the formula (I), or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is selected from:
• C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl-, wherein R1 is substituted by at least one fluorine;
• optionally wherein one or more H in R1 is substituted by D;
• R2 is selected from:
• H, D, C1-6 alkyl and C1-6 haloalkyl;
• or
• R1 and R2 together with the carbon atom to which they are attached form a C3.6 cycloalkyl substituted with at least one fluorine;
• R3 is selected from:
• C1-6 alkyl and C1-6 haloalkyl;
• optionally wherein one or more H in R3 is substituted by D;
• L is selected from:
• a bond and C1-3 alkylene;
• Ring A is selected from:
• C3-6 cycloalkyl, 4- to 7-membered heterocyclyl, 5- to 12-membered heteroaryl and C6-10 aryl;
• wherein Ring A is optionally substituted by one or more R4;
• each R4 is independently selected from:
• halo, —CN, —NO2, ═O, C1-6 alkyl, C1-6 haloalkyl, 2 to 8 membered heteroalkyl, C2-6 alkenyl, C2-6 alkynyl, Q1, —OR5, —S(O)xR, —NR5R6, —C(O)R5, —OC(O)R5, —C(O)OR5, —NR5C(O)R6, —C(O)NR5R6, —NR5C(O)OR6, —OC(O)NR5R6, —NR5SO2R6, and —SO2NR5R6,
• wherein said C1-6 alkyl, 2 to 8 membered heteroalkyl, C2-6 alkenyl and C2-6 alkynyl is optionally substituted by one or more R7;
• R5 and R6 are each independently selected from:
• H, C1-6 alkyl, C1-6 haloalkyl and Q1,
• wherein said C1-6 alkyl is optionally substituted by one or more R8;
• each R7 and R8 is independently selected from:
• halo, —CN, —OR7A, —S(O)xR7A, —NR7AR7B, C(O)R7A, —OC(O)R7A, —C(O)OR7A, —NR7AC(O)R7B, —C(O)NR7AR7B and Q2;
• each Q1 and Q2 is independently selected from:
• C3-6 cycloalkyl, 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl,
• wherein said C3-6 cycloalkyl, 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl is optionally substituted by one or more R9;
• each R9 is independently selected from:
• halo, —O, —CN, —NO2, C1-4 alkyl, C1-4 haloalkyl, —OR9A, —S(O)2R9A, —NR9AR9B, —C(O)R9A, —OC(O)R9A, —C(O)OR9A, —NR9BC(O)R9A, —C(O)NR9AR9B, —NR9BC(O)OR9A, —OC(O)NR9AR9B, —NR9BSO2R9A and —SO2NR9AR9B,
• wherein said C1-4 alkyl is optionally substituted by 1 or 2 substituents selected from:
• halo, —CN, —OR9C, —NR9CR9D and —SO2R9C;
• Ring B is phenyl or a 5- or 6-membered heteroaryl, wherein Ring B is optionally substituted by one or more R10;
• each R10 is independently selected from:
• halo, —CN, —NO2, ═O, C1-6 alkyl, C1-6 haloalkyl, 2 to 8 membered heteroalkyl, C2-6 alkenyl, C2-6 alkynyl, —OR10A, —S(O)xR10A, —NR10AR10B, —C(O)R10A, —OC(O)R10A, —C(O)OR10A, —NR10AC(O)R10B, —C(O)NR10AR10B, —NR10AC(O)OR10B, —OC(O)NR10AR10B, —NR10ASO2R10B, and —SO2NR10AR10B,
• wherein said C1-6 alkyl, 2 to 8 membered heteroalkyl, C2-6 alkenyl and C2-6 alkynyl is optionally substituted by one or more R11;
• each R11 is independently selected from:
• halo, —CN, —OR11A, —NR11AR11B and —SO2R11A,
• R7A, R7B, R9A, R9B, R9C, R9D, R10A, R10B, R11A and R11B are at each occurrence independently selected from:
• H, C1-4 alkyl and C1-4 haloalkyl;
• and wherein any —NR5R6, —NR7AR7B, —NR9AR9B, —NR9CR9D, —NR10AR10B, and —NR11AR11B within a substituent may form a 4- to 6-membered heterocyclyl,
• wherein said 4- to 6-membered heterocyclyl is optionally substituted by one or more substituents selected from:
• halo, ═O, C1-4 alkyl and C1-4 haloalkyl;
• each x is independently 0, 1, or 2;
• with the following provisos:
• (i) that when the group
• wherein R41 is H, —CH3, —CF3 or cyclopropyl, then R42 is not —NHC(O)R6;
• and
• (ii) that Compounds A and B are excluded: